Business Context and Reporting Period
This Form 8-K is a current report filed by Celsus Therapeutics Plc (note: metadata lists Akari Therapeutics Plc, but the filing text identifies Celsus Therapeutics Plc) on April 9, 2015. The report addresses a regulatory notice regarding the company's listing status on The NASDAQ Stock Market.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The only quantitative metric disclosed is the market price of the company's American Depositary Shares (ADSs), which fell below $1.00 per ADS for 30 consecutive business days.
Material Changes
The primary material event is the receipt of a written notification from NASDAQ indicating non-compliance with Listing Rule 5450(a)(2) due to the minimum bid price deficiency. Consequently, the company has been granted a 180-calendar day compliance period ending October 6, 2015, to regain compliance.
Outlook, Risks, and Management Commentary
- Compliance Requirement: To regain compliance, the closing bid price of the ADSs must meet or exceed $1.00 for at least ten consecutive business days during the grace period.
- Future Options: If the company fails to comply by October 6, 2015, it may be eligible for a second 180-day grace period, provided it meets other listing standards and notifies NASDAQ of its intent to cure the deficiency, potentially via a reverse stock split.
- Delisting Risk: Failure to regain compliance within the allotted periods could result in delisting. The company retains the right to appeal such a determination to a NASDAQ Hearings Panel.
- Management Stance: The company intends to consider available options to resolve the noncompliance but has made no determination regarding its specific response at this time. There is no assurance that compliance will be achieved.
Investor Verification Checklist
- Verify the current trading price of Celsus Therapeutics Plc ADSs to assess progress toward the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split or other capital structure changes intended to address the bid price deficiency.
- Review the company's most recent Form 10-K for detailed risk factors and financial condition not included in this 8-K.
- Track the October 6, 2015 deadline for the initial compliance period.